DAIICHI SANKYO, INC.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
- Conditions
- Advanced Colorectal Cancer
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 122
- Registration Number
- NCT04744831
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 179
- Registration Number
- NCT04707248
- Locations
- 🇺🇸
Arizona Oncology Associates, PC HOPE (A)A HOPE), Tucson, Arizona, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Florida Cancer Lake Mary, Lake Mary, Florida, United States
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- Conditions
- Gastroesophageal Junction AdenocarcinomaGastric Cancer, Adenocarcinoma
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 490
- Registration Number
- NCT04704934
- Locations
- 🇦🇷
Instituto Medico Especializado Alexander Fleming, Colegiales, Caba, Argentina
🇦🇷IONC Instituto Oncologico de Cordoba - Fundacion Richardet Longo, Nueva Cordoba, Cordoba, Argentina
🇦🇷Exelsus, San Miguel De Tucumán, Tucumán, Argentina
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
- Conditions
- Relapsed/Refractory Peripheral T-Cell LymphomaAdult T Cell Leukemia/Lymphoma
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 155
- Registration Number
- NCT04703192
- Locations
- 🇺🇸
City Of Hope National Medical Center, Duarte, California, United States
🇺🇸Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY, Palo Alto, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: HER3-DXd
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 246
- Registration Number
- NCT04676477
- Locations
- 🇺🇸
UCLA, Santa Monica, California, United States
🇺🇸Yale University School of Medicine - Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 590
- Registration Number
- NCT04656652
- Locations
- 🇺🇸
Ironwood Cancer and Research Center, Chandler, Arizona, United States
🇺🇸St. Joseph Heritage Healthcare, Anaheim, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Glendale, California, United States
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 152
- Registration Number
- NCT04644237
- Locations
- 🇺🇸
University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸AdventHealth Orlando, Orlando, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
- Conditions
- Tenosynovial Giant Cell TumorHepatotoxicity
- Interventions
- Drug: TURALIO™
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 30
- Registration Number
- NCT04635111
- Locations
- 🇺🇸
Kamalesh K Sankhala MD INC, Santa Monica, California, United States
🇺🇸Sarcoma Oncology Research Center LLC, Santa Monica, California, United States
🇺🇸UCLA Hematology and Oncology, Santa Monica, California, United States
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
- Conditions
- HER2-Positive Primary Breast CancerResidual Invasive Breast Cancer
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1600
- Registration Number
- NCT04622319
- Locations
- 🇺🇸
The Oncology Institute of Hope & Innovation, Anaheim, California, United States
🇺🇸Kaiser Permanente, Woodland Hills, California, United States
🇺🇸Orange Coast Blood and Cancer Care, Fountain Valley, California, United States
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 277
- Registration Number
- NCT04619004
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Moores Cancer Center at the UC San Diego Health, La Jolla, California, United States